Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Inclusion Criteria:

Subject has at least 1 year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, including the following:

1. Migraine attacks present for more than 1 year with the age of onset prior to 50years of age.

2. Migraine attacks, on average, lasting about 4-72 hours if untreated.

3. Not more than 8 attacks of moderate to severe intensity per month within the last 3months.

4. Ability to distinguish migraine attacks from tension/cluster headaches.

5. Consistent migraine headaches of at least 2 migraine headache attacks of moderate orsevere intensity in each of the 3 months prior to Screening Visit and maintains thisrequirement during the Screening period.

6. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to Screening Visit and maintains this requirement during theScreening Period.

7. Subjects on prophylactic migraine medication are permitted to remain on therapy ifthe dose has been stable for at least 3 months prior to the Screening Visit, and ifthe dose is not expected to change during the course of the study.

8. Subjects with contraindications for use of triptans may be included provided theymeet all other study entry criteria.

Exclusion Criteria:

1. Subject has a history of migraine with brainstem aura (basilar migraine), hemiplegicmigraine or retinal migraine.

2. History of use of analgesics (e.g. nonsteroidal anti-inflammatory drugs [NSAIDs] oracetaminophen) on ≥ 15 days per month during the 3 months (12 weeks) prior to theScreening Visit.

3. Subject history with current evidence of uncontrolled, unstable or recentlydiagnosed cardiovascular disease, such as ischemic heart disease, coronary arteryvasospasm, and cerebral ischemia. Subjects with Myocardial Infarction (MI), AcuteCoronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery,stroke or transient ischemic attack (TIA) during the 6 months prior to screening.

4. Uncontrolled hypertension or uncontrolled diabetes (however subjects can be includedwho have stable hypertension and/or diabetes for at least 3 months prior toscreening).

5. Subject with other pain syndromes, psychiatric conditions, dementia, or significantneurological disorders (other than migraine) that, in the Investigator's opinion,interfere with study assessments.

6. Subject has a history of gastric, or small intestinal surgery (including GastricBypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has a diseasethat causes malabsorption.

7. The subject has a history or current evidence of any unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known or suspectedinfection, hepatitis B or C, or cancer) that, in the investigator's opinion, wouldexpose them to undue risk of a significant adverse event (AE) or interfere withassessments of safety or efficacy during the course of the trial.

8. History of alcohol abuse and/or illicit drug use meeting DSM-V criteria forsubstance use disorder within 6 months of screening.

9. Participation in any other investigational clinical trial while participating inthis clinical trial.